| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2006. Published by Oxford University Press.
ARTICLE |
Effect of Connective Tissue Growth Factor on Hypoxia-Inducible Factor 1
Degradation and Tumor Angiogenesis
Affiliations of authors: Angiogenesis Research Center, Laboratory of Molecular and Cellular Toxicology, Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan (CCC, MLK); Departments of Surgery (MTL, BRL, KJC), Pathology (YMJ), Pediatrics (STC), and Dermatology (CYC), National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan (RJC); Department of Internal Medicine, National Taiwan University Hospital, National Health Research Institutes, and Institute of Biomedical Sciences, Taipei, Taiwan (PCY).
Correspondence to: Min-Liang Kuo, PhD, Angiogenesis Research Center, Laboratory of Molecular and Cellular Toxicology, Institute of Toxicology, College of Medicine, National Taiwan University, No. 1 Sec. 1 Jen-Ai Rd., Taipei 100, Taiwan (e-mail: toxkml{at}ha.mc.ntu.edu.tw).
Background: Connective tissue growth factor (CTGF) inhibits the metastatic activity of human lung cancer cells in a mouse model; however, the mechanism of this modulation is unclear. We investigated the role of angiogenesis in this process. Methods: CL1-5 and A549 human lung adenocarcinoma cells were stably transfected with vectors containing CTGF or hypoxia-inducible factor (HIF) 1
or with vector controls. Transfected cells were injected into nude mice (n = 10 per group), and tumor growth, metastasis, and mouse survival were measured. Excised xenograft tumors and primary human lung adenocarcinomas (n = 24) were subjected to immunohistochemistry with antibodies to the endothelial cell marker CD31 and to CTGF. Expression of HIF-1 and vascular endothelial growth factor (VEGF) A was assessed in vitro by using reporter gene assays. Cells were transiently transfected with HIF-1 mutant and antisense arrest-defective 1 protein (ARD-1), and HIF-1 acetylation was assayed by immunoprecipitation. All statistical tests were two-sided. Results: Xenograft tumors derived from CTGF transfectants grew more slowly than those from control-transfected cells and had reduced expression of HIF-1 and VEGF-A, vascularization (as assessed by CD31 expression), and metastasis (all P<.001). Xenograft tumors derived from CTGF-overexpressing cells that were transfected with HIF-1 had higher VEGF-A expression than CTGF-overexpressing xenografts. Mice with CTGF/HIF-1 xenografts had lower survival than mice carrying CTGF-overexpressing xenografts (CL1-5/Neo, mean = 69.6 days, 95% confidence interval [CI] = 53.9 to 85.3 days versus CL1-5/CTGF, mean = 102.1 days, 95% CI = 92.1 to 112.1 days; P = .001, CL1-5/CTGF, mean = 102.1 days, 95% CI = 92.1 to 112.1 days versus CL1-5/CTGF/HIF-1, mean = 81.7 days, 95% CI = 66.5 to 96.9 days; P = .011, CL1-5/Neo, mean = 69.6 days, 95% CI = 53.9 to 85.3 days versus CL1-5/CTGF/HIF-1, mean = 81.7 days, 95% CI = 66.5 to 96.9 days; P = .122). Tumors of patients with the same disease stage but with high CTGF protein expression had reduced microvessel density compared with tumors with low expression. Transfection with antisense-ARD1 decreased the level of acetylated HIF-1 and restored HIF-1 and VEGF-A expression in CTGF-overexpressing cells. Conclusion: CTGF inhibition of metastasis involves the inhibition of VEGF-A–dependent angiogenesis, possibly by promoting HIF-1 protein degradation.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
-
Choking Hypoxia-Inducible Factor 1: A Novel Mechanism for Connective Tissue Growth Factor Inhibition of Angiogenesis
- Francesca Tosetti, Douglas M. Noonan, and Adriana Albini
J Natl Cancer Inst 2006 98: 946-948.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  J. Samarin, M. Rehm, B. Krueger, J. Waschke, and M. Goppelt-Struebe Up-Regulation of Connective Tissue Growth Factor in Endothelial Cells by the Microtubule-Destabilizing Agent Combretastatin A-4 Mol. Cancer Res., February 1, 2009; 7(2): 180 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-H. Li, T. Sanchez, A. Pappalardo, K. R. Lynch, T. Hla, and F. Ferrer Induction of Antiproliferative Connective Tissue Growth Factor Expression in Wilms' Tumor Cells by Sphingosine-1-Phosphate Receptor 2 Mol. Cancer Res., October 1, 2008; 6(10): 1649 - 1656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Smerdel-Ramoya, S. Zanotti, L. Stadmeyer, D. Durant, and E. Canalis Skeletal Overexpression of Connective Tissue Growth Factor Impairs Bone Formation and Causes Osteopenia Endocrinology, September 1, 2008; 149(9): 4374 - 4381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Alvarez, A. Corvalan, J. C. Roa, P. Argani, F. Murillo, J. Edwards, R. Beaty, G. Feldmann, S.-M. Hong, M. Mullendore, et al. Serial Analysis of Gene Expression Identifies Connective Tissue Growth Factor Expression as a Prognostic Biomarker in Gallbladder Cancer Clin. Cancer Res., May 1, 2008; 14(9): 2631 - 2638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Kuiper, P. Roestenberg, C. Ehlken, V. Lambert, H. B. van Treslong-de Groot, K. M. Lyons, H.-J. T. Agostini, J.-M. Rakic, I. Klaassen, C. J.F. Van Noorden, et al. Angiogenesis Is Not Impaired in Connective Tissue Growth Factor (CTGF) Knock-out Mice J. Histochem. Cytochem., November 1, 2007; 55(11): 1139 - 1147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Khan, F. Afaq, M.-H. Kweon, K. Kim, and H. Mukhtar Oral Consumption of Pomegranate Fruit Extract Inhibits Growth and Progression of Primary Lung Tumors in Mice Cancer Res., April 1, 2007; 67(7): 3475 - 3482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Tosetti, D. M. Noonan, and A. Albini Choking hypoxia-inducible factor 1alpha: a novel mechanism for connective tissue growth factor inhibition of angiogenesis. J Natl Cancer Inst, July 19, 2006; 98(14): 946 - 948. [Full Text] [PDF]
|
|